Nexstim Plc (HEL:NXTMH)
Finland · Delayed Price · Currency is EUR | Market Cap | 72.67M +27.7% |
| Revenue (ttm) | 12.41M +21.5% |
| Net Income | 573.20K |
| EPS | 0.06 |
| Shares Out | 8.07M |
| PE Ratio | 150.00 |
| Forward PE | 75.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,495 |
| Open | 9.16 |
| Previous Close | 9.15 |
| Day's Range | 9.00 - 9.18 |
| 52-Week Range | 7.89 - 16.45 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Nexstim
Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor defici... [Read more]
Financial Performance
Financial StatementsNews
Nexstim Earnings Call Transcript: H2 2025
Revenue grew 26% to EUR 11m in 2025, with record system sales and high gross margins. Strategic partnerships and new product launches drove growth, while recurring revenue saw a temporary dip due to customer purchasing shifts.
Nexstim Annual report: H2 2025
Nexstim has published its H2 2025 annual report on February 26, 2026.
Nexstim Quarterly report: H2 2025
Nexstim has published its H2 2025 quarterly earnings report on February 26, 2026.
Nexstim Slides: H2 2025
Nexstim has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
Nexstim Quarterly report: H2 2025
Nexstim has published its H2 2025 quarterly earnings report on February 26, 2026.
Nexstim Slides: H2 2025
Nexstim has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
Nexstim Transcript: Life Science Summit 2025
The company leverages proprietary TMS technology for brain diagnostics and therapy, achieving strong sales growth, high margins, and profitability. Strategic partnerships and international expansion, especially in Asia, are key growth drivers, while long sales cycles and hospital budget constraints remain challenges.
Nexstim Earnings Call Transcript: H1 2025
Revenue grew 42% in H1 2025, led by diagnostics and new partnerships, with positive EBITDA and strong gross margins. Outlook for 2025 remains positive, supported by the launch of the modular NBS 6 system and continued expansion in diagnostics, therapy, and research.
Nexstim Quarterly report: H1 2025
Nexstim has published its H1 2025 quarterly earnings report on August 15, 2025.
Nexstim Slides: H1 2025
Nexstim has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 15, 2025.
Nexstim Quarterly report: H1 2025
Nexstim has published its H1 2025 quarterly earnings report on August 15, 2025.
Nexstim Slides: H1 2025
Nexstim has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 15, 2025.